Cargando…

Evaluating Treatment Patterns, Relapses, Healthcare Resource Utilization, and Costs Associated with Disease-Modifying Treatments for Multiple Sclerosis in DMT-Naïve Patients

PURPOSE: Early diagnosis and treatment of multiple sclerosis (MS) with disease-modifying therapy (DMT) can reduce relapse number and severity, which has cost implications. We describe treatment patterns, healthcare utilization, and cost among MS patients newly initiating DMTs (index). PATIENTS AND M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Freeman, Leorah, Kee, Arianna, Tian, Marc, Mehta, Rina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837567/ https://www.ncbi.nlm.nih.gov/pubmed/33519217 http://dx.doi.org/10.2147/CEOR.S288296

Ejemplares similares

Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
por: Freeman, Leorah, et al.
Publicado: (2021)

High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis
por: Freeman, Léorah, et al.
Publicado: (2022)

Lymphopenia in treatment-naive relapsing multiple sclerosis
por: Lim, Zhi Wei, et al.
Publicado: (2016)

Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel(®)
por: Gold, Laura S., et al.
Publicado: (2016)

Treatment Patterns, Healthcare Resource Utilization, and Costs Among Medicare Patients with Multiple Sclerosis in Relation to Disease-Modifying Therapy and Corticosteroid Treatment
por: Sanchirico, Marie, et al.
Publicado: (2018)

Treatment Patterns, Health Care Resource Utilization, and Cost in Patients with Myelofibrosis in the United States
por: Copher, Ronda, et al.
Publicado: (2022)

Cost-utility analysis of teriflunomide in naïve vs. previously treated patients with relapsing–remitting multiple sclerosis in Italy
por: Lazzaro, Carlo, et al.
Publicado: (2022)

Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis
por: Burks, Jack, et al.
Publicado: (2017)

Real-World Treatment Patterns of Disease Modifying Therapy (DMT) for Patients with Relapse-Remitting Multiple Sclerosis and Patient Satisfaction with Therapy: Results of the Non-Interventional SKARLET Study in Slovakia
por: Turčáni, Peter, et al.
Publicado: (2020)

Resource utilization, costs and treatment patterns of switching and discontinuing treatment of MS patients with high relapse activity
por: Raimundo, Karina, et al.
Publicado: (2013)

The Association Between Persistence and Adherence to Disease-Modifying Therapies and Healthcare Resource Utilization and Costs in Patients With Multiple Sclerosis
por: Pardo, Gabriel, et al.
Publicado: (2022)

Cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran
por: Imani, Ali, et al.
Publicado: (2012)

Impact on healthcare resource utilization of multiple sclerosis in Spain
por: Sicras-Mainar, Antoni, et al.
Publicado: (2017)

Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT
por: Barker, Steven A.
Publicado: (2022)

Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims Data
por: Nicholas, Jacqueline, et al.
Publicado: (2017)

Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclerosis
por: Bonafede, Machaon, et al.
Publicado: (2020)

Serum Leptin Levels in Treatment-Naive Patients with Clinically Isolated Syndrome or Relapsing-Remitting Multiple Sclerosis
por: Evangelopoulos, Maria Eleftheria, et al.
Publicado: (2014)

The effectiveness of teriflunomide in patients with multiple sclerosis in China: a real-world comparison to no DMT treatment in the first year after diagnosis
por: Bu, Bitao, et al.
Publicado: (2023)

Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis
por: Mankinen, Petri, et al.
Publicado: (2019)

Cost-effectiveness of ocrelizumab for treatment of Iranian patients with relapsing multiple sclerosis
por: Ayati, Nayyereh, et al.
Publicado: (2021)

Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis
por: Wu, Jashin J., et al.
Publicado: (2020)

Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis
por: Schultz, Neil M., et al.
Publicado: (2018)

DMT Models the Near-Death Experience
por: Timmermann, Christopher, et al.
Publicado: (2018)

DMT alters cortical travelling waves
por: Alamia, Andrea, et al.
Publicado: (2020)

Comparing the Cost-Effectiveness of Disease-Modifying Drugs for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis
por: Goldberg, Lawrence, et al.
Publicado: (2009)

Impact of Endometriosis Diagnostic Delays on Healthcare Resource Utilization and Costs
por: Surrey, Eric, et al.
Publicado: (2020)

Healthcare resource utilization and costs associated with anogenital warts in Morocco
por: Berrada, Myriam, et al.
Publicado: (2021)

Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
por: Michels, Renée Else, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
por: Baharnoori, Moogeh, et al.
Publicado: (2022)

Cost–consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada
por: Bhan, Virender, et al.
Publicado: (2023)

Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: Comparison between centre-based and local service healthcare delivery
por: Moccia, Marcello, et al.
Publicado: (2019)

Medication Adherence and Healthcare Utilization in Relapsing-Remitting Multiple Sclerosis Patients Using Teriflunomide
por: Greene, Nupur, et al.
Publicado: (2022)

Predicting the Impact of Adverse Events and Treatment Duration on Medical Resource Utilization-Related Costs in Hepatitis C Genotype 1 Treatment-Naïve Patients Receiving Antiviral Therapy
por: Akpo, Essè Ifèbi Hervé, et al.
Publicado: (2015)

Epidemiology, treatment patterns and healthcare utilizations in multiple sclerosis in Taiwan
por: Hsu, Chia-Yun, et al.
Publicado: (2021)

Analysis of Healthcare Resource Utilization and Costs after the Initiation of Biologic Treatment in Patients with Ulcerative Colitis and Crohn’s Disease
por: Perera, Sue, et al.
Publicado: (2018)

The cost of relapse and the predictors of relapse in the treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2010)

A qualitative study assessing patient perspectives in the process of decision-making on disease modifying therapies (DMT’s) in multiple sclerosis (MS)
por: de Ceuninck van Capelle, Archibald, et al.
Publicado: (2017)

Treatment patterns, healthcare resource utilization, and healthcare costs among patients with pulmonary arterial hypertension in a real-world US database
por: Studer, Sean, et al.
Publicado: (2018)

Dense module searching for gene networks associated with multiple sclerosis
por: Manuel, Astrid M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vte60fvd7onvju9bbbhqhugp3g